MDMA-Authorised Prescriber approval PTSD, page-5

  1. 5,626 Posts.
    lightbulb Created with Sketch. 869
    YES
    (ASX:EMD) 's specialist psychiatrist has been granted Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) for MDMA-assisted therapy in post-traumatic stress disorder (PTSD) care.


    This is a major milestone for the company, as MDMA-assisted therapy has been explored as a treatment for PTSD in multiple Phase 3 clinical trials conducted in the USA. The approval allows Emyria to expand its service offerings beyond clinical trials and into real-world treatment
    Last edited by Telluride: 09/05/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
3.8¢
Change
0.004(11.8%)
Mkt cap ! $23.23M
Open High Low Value Volume
3.4¢ 3.8¢ 3.4¢ $261.7K 7.375M

Buyers (Bids)

No. Vol. Price($)
1 199597 3.7¢
 

Sellers (Offers)

Price($) Vol. No.
3.8¢ 31358 1
View Market Depth
Last trade - 16.10pm 23/07/2025 (20 minute delay) ?
EMD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.